Prognostic significance of m>P2RY8-CRLF2m> and m>CRLF2m> overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia

详细信息    查看全文

• 作者：Hu Dou ; Xi Chen ; Yi Huang ; Yongchun Su ; Ling Lu ; Jie Yu ; Yibing Yin and Liming Bao
• 刊名：Genes, Chromosomes and Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：56
• 期：2
• 页码：135-146
• 全文大小：259K
• ISSN：1098-2264

文摘

The cytokine receptor-like factor 2 (m>CRLF2m>) gene plays an important role in early B-cell development. Aberrations in m>CRLF2m> activate the JAK-STAT signaling pathway that contributes to B-cell acute lymphoblastic leukemia (B-ALL). The prognostic significance of m>CRLF2m> overexpression and m>P2RY8-CRLF2m> fusion in various B-ALL risk subgroups has not been well established. Two hundred seventy-one patients with newly diagnosed childhood B-ALL were enrolled from a Chinese population. The prevalence of m>CRLF2m> overexpression, m>CRLF2-P2RY8m> fusion, m>CRLF2m> F232C mutation, and m>JAK2m> and m>IL7Rm> mutational status were analyzed, and the prognostic impact of m>CRLF2m> overexpression and m>P2RY8-CRLF2m> on B-ALL was evaluated by assessing their influence on overall survival and event-free survival. m>CRLF2m> overexpression and m>P2RY8-CRLF2m> were found in 19% and 10%, respectively, in the whole cohort. No correlation between m>CRLF2m> overexpression and m>P2RY8-CRLF2m> was observed. m>CRLF2m> F322C and m>IL7Rm> mutations were not detected in B-ALL cases overexpressing m>CRLF2m>, and no m>JAK2m> mutations were found in the whole cohort either. The results showed that m>CRLF2m> overexpression and m>P2RY8-CRLF2m> were associated with a poor outcome in unselected B-ALL. Moreover, in an intermediate risk B-ALL subgroup m>P2RY8-CRLF2m> was correlated with worse survival, whereas in high- and low-risk subgroups, m>CRLF2m> overexpression predicted a poor outcome. Our findings suggest that m>P2RY8-CRLF2m> is an independent prognostic indicator in intermediate risk B-ALL, while m>CRLF2m> overexpression is correlated with an inferior outcome in high- or low-risk B-ALL. Our study demonstrates that the impact of m>P2RY8-CRLF2m> and m>CRLF2m> overexpression on B-ALL survival may differ across risk subgroups.